prikaz prve stranice dokumenta The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status
  Download
PDF 5.57 MB
Scientific paper - Original scientific paper
The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status
Biomolecules and Biomedicine, 24 (2024), 2; 256-261. https://doi.org/10.17305/bb.2023.9868
Gatalica, Zoran; Kuzmova, Nataliya; Rose, Inga; Ulamec, Monika; Perić-Balja, Melita; Skenderi, Faruk; Vranic, Semir

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Gatalica, Z., Kuzmova, N., Rose, I., Ulamec, M., Perić Balja, M., Skenderi, F. & Vranic, S. (2024). The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status. Biomolecules and Biomedicine, 24. (2), 256-261. doi: 10.17305/bb.2023.9868

Gatalica, Zoran, et al. "The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status." Biomolecules and Biomedicine, vol. 24, no. 2, 2024, pp. 256-261. https://doi.org/10.17305/bb.2023.9868

Gatalica, Zoran, Nataliya Kuzmova, Inga Rose, Monika Ulamec, Melita Perić Balja, Faruk Skenderi and Semir Vranic. "The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status." Biomolecules and Biomedicine 24, no. 2 (2024): 256-261. https://doi.org/10.17305/bb.2023.9868

Gatalica, Z., et al. (2024) 'The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status', Biomolecules and Biomedicine, 24(2), pp. 256-261. doi: 10.17305/bb.2023.9868

Gatalica Z, Kuzmova N, Rose I, Ulamec M, Perić Balja M, Skenderi F, and sur.. The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status. Biomolecules and Biomedicine [Internet]. 2024 March 11 [cited 2024 November 29];24(2):256-261. doi: 10.17305/bb.2023.9868

Z. Gatalica, et al., "The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status", Biomolecules and Biomedicine, vol. 24, no. 2, pp. 256-261, March 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:253311. [Accessed: 29 November 2024]

Metadata
Title (english)The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status
AuthorZoran Gatalica
MBZ: 138016
AuthorNataliya Kuzmova
AuthorInga Rose
AuthorMonika Ulamec
AuthorMelita Perić-Balja
AuthorFaruk Skenderi
AuthorSemir Vranic
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract (english)
In the current study, we assessed the prevalence and molecular features of HER2-low phenotype in the apocrine carcinomas of the breast (ApoCa) and its relationship with tumor-infiltrating lymphocytes (TILs). A cohort of 64 well-characterized therapy-naïve ApoCa was used. The TIL distribution was assessed using the hematoxylin and eosin whole slide/scanned images following the international TILs working group recommendations. Next-generation sequencing (NGS) was performed in a subset of HER2-low ApoCa. All patients were women, with a mean age of 62 years. Forty-three carcinomas were pure apocrine carcinoma (PAC; ER−/AR+), and the remaining 21 were classified as apocrine-like carcinomas (ALCs; ER+/−, AR+/−). HER2/neu was positive (score 3+ by IHC and/or amplified by FISH) in 20/43 (47%) PAC and 4/21 (19%) ALC. The prevalence of HER2-low expression (scores 1+ or 2+ without HER2 amplification) in ApoCa was 39% without significant differences between PAC and ALC (P = 0.14); however, the HER2-low phenotype was more prevalent in triple-negative PAC than in ALC (P < 0.001). Levels of TILs were low (≤10%) in 74% of ApoCa (median 5%, range 0%–50%). TIL levels were significantly higher in ALC than in PAC (P = 0.02). HER2 status had no impact on TIL distribution (P = 0.45). The genomic profile of HER2-low ApoCa was similar to other subtypes of ApoCa. ApoCa has predominantly low TIL, particularly PAC. The prevalence of the HER2-low phenotype in ApoCa is high, which should have therapeutic and clinical implications given the recently approved therapies with antibody–drug conjugates (ADCs) for HER2-low breast cancers.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomolecules and Biomedicine
Numberingvol. 24, no. 2, pp. 256-261
p-ISSN2831-0896
e-ISSN2831-090X
DOIhttps://doi.org/10.17305/bb.2023.9868
URN:NBNurn:nbn:hr:105:253311
Publication2024-03-11
Document URLhttps://bjbms.org/ojs/index.php/bjbms/article/view/9868
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-05-20 07:42:03